Patents by Inventor David S. Thomson

David S. Thomson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Glucocorticoid mimetics, methods of making them, pharmaceutical formulations, and uses thereof
    Patent number: 6960581
    Abstract: A compound of Formula (I) wherein R1, R2, R3, R4, R5, and R6 are as defined herein, or a tautomer, prodrug, solvate, or salt thereof, pharmaceutical compositions containing such compounds, and methods of modulating the glucocorticoid receptor function and methods of treating disease-states or conditions mediated by the glucocorticoid receptor function or characterized by inflammatory, allergic, or proliferative processes in a patient using these compounds.
    Type: Grant
    Filed: January 3, 2003
    Date of Patent: November 1, 2005
    Assignee: Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Rajashekhar Betageri, David S. Thomson, Yan Zhang, Renee Michele Zindell
  • Cyanoamido-containing heterocyclic compounds useful as reversible inhibitors of cysteine proteases
    Patent number: 6936606
    Abstract: Disclosed are novel cathepsin S, K, F, L and B reversible inhibitory compounds of the formulas (Ia) and (Ib) where R1, R2, R3, R4, R5, R6, R8, R9 and X are defined herein. The compounds are useful for treating autoimmune and other diseases.
    Type: Grant
    Filed: September 27, 2002
    Date of Patent: August 30, 2005
    Assignee: Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Younes Bekkali, Denice Mary Spero, Sanxing Sun, David S. Thomson, Yancey D. Ward, Erick R. R. Young, Eugene R. Hickey, Weimin Liu, Usha R. Patel
  • Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
    Patent number: 6903215
    Abstract: Compounds of Formula (IA) and Formula (IB) wherein R1, R2, R3, R4, R5, and R6 are as defined herein for Formula (IA) or Formula (IB), or a tautomer, prodrug, solvate, or salt thereof; pharmaceutical compositions containing such compounds, and methods of modulating the glucocorticoid receptor function and methods of treating disease-states or conditions mediated by the glucocorticoid receptor function or characterized by inflammatory, allergic, or proliferative processes in a patient using these compounds.
    Type: Grant
    Filed: March 21, 2003
    Date of Patent: June 7, 2005
    Assignee: Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Rajashehar Betageri, Thomas A. Gilmore, Christian Hanke Justus Joachim Harcken, Daniel Kuzmich, Doris Riether, David S. Thomson, Ji Wang, Hossein Razavi
  • Compounds useful as reversible inhibitors of cysteine proteases
    Patent number: 6858623
    Abstract: Disclosed are novel cathepsin S, K, F, L and B reversible inhibitory compounds of the formula (Ia) and (Ib) where R2, R3, R4, R5, R6, R7, R8, Het and X are defined herein. The compounds are useful for treating autoimmune and other diseases. Also disclosed are processes for making such novel compounds.
    Type: Grant
    Filed: May 29, 2003
    Date of Patent: February 22, 2005
    Assignee: Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Younes Bekkali, Eugene R. Hickey, Weimin Liu, Usha R. Patel, Denice M. Spero, Sanxing Sun, David S. Thomson, Yancey D. Ward, Erick R. R. Young
  • Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
    Patent number: 6858627
    Abstract: Compounds of Formula (I) wherein R1, R2, R3, R4, R5, R6, X, Y, and n are as defined herein, or a tautomer, prodrug, solvate, or salt thereof; pharmaceutical compositions containing such compounds, and methods of modulating the glucocorticoid receptor function and methods of treating disease-states or conditions mediated by the glucocorticoid receptor function or characterized by inflammatory, allergic, or proliferative processes in a patient using these compounds.
    Type: Grant
    Filed: August 12, 2003
    Date of Patent: February 22, 2005
    Assignee: Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Younes Bekkali, Thomas Gilmore, Denice Mary Spero, Hidenori Takahashi, David S. Thomson, Ji Wang
  • Compounds useful as reversible inhibitors of cysteine proteases
    Patent number: 6787540
    Abstract: Disclosed are novel cathepsin S, K, F, L and B reversible inhibitory compounds of the formula (Ia) and (Ib) where R2, R3, R4, R5, R6, R7, R8, Het and X are defined herein. The compounds are useful for treating autoimmune and other diseases. Also disclosed are processes for making such novel compounds.
    Type: Grant
    Filed: October 1, 2002
    Date of Patent: September 7, 2004
    Assignee: Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Younes Bekkali, Eugene R. Hickey, Weimin Liu, Usha R. Patel, Denice M. Spero, Sanxing Sun, David S. Thomson, Yancey D. Ward, Erick R. R. Young
  • Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
    Publication number: 20040162321
    Abstract: Compounds of Formula (I) 1
    Type: Application
    Filed: December 18, 2003
    Publication date: August 19, 2004
    Applicant: Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Daniel Kuzmich, Thomas Wai-Ho Lee, John Robert Proudfoot, John Robinson Regan, David S. Thomson, Abdelhakim Hammach, Mark Stephen Ralph, Renee Zindell
  • Compounds useful as reversible inhibitors of cysteine proteases
    Patent number: 6756372
    Abstract: Disclosed are novel cathepsin S, K, F, L and B reversible inhibitory compounds of the formulas (I), (II), (Ia) and (Ib) further defined herein. The compounds are useful for treating autoimmune diseases. Also disclosed are processes for making such novel compounds.
    Type: Grant
    Filed: November 2, 2001
    Date of Patent: June 29, 2004
    Assignee: Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Michel Jose Emmanuel, Weimin Liu, Denice Mary Spero, Sanxing Sun, David S. Thomson, Yancey David Ward
  • Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
    Publication number: 20040116455
    Abstract: Compounds of Formula (I) 1
    Type: Application
    Filed: August 12, 2003
    Publication date: June 17, 2004
    Applicant: Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Younes Bekkali, Thomas Gilmore, Denice Mary Spero, Hidenori Takahashi, David S. Thomson, Ji Wang
  • Compounds useful as reversible inhibitors of cathespin S
    Patent number: 6730671
    Abstract: Disclosed are cathepsin S reversible inhibitory compounds of the formulas (I),(Ia) and (II),(IIa) as defined herein. The compounds are useful for treating autoimmune diseases. Also disclosed are processes, for making such novel compounds.
    Type: Grant
    Filed: February 13, 2003
    Date of Patent: May 4, 2004
    Assignee: Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Charles L. Cywin, Michel J. Emmanuel, Tina Morwick, Denice M. Spero, David S. Thomson, Yancey D. Ward
  • Compounds useful as reversible inhibitors of cysteine proteases
    Patent number: 6720319
    Abstract: Disclosed are novel cathepsin S, K, F, L and B reversible inhibitory compounds of the formula (Ia) and (Ib) where R2, R3, R4, R5, R6, R7, R8, Het and X are defined herein. The compounds are useful for treating autoimmune and other diseases. Also disclosed are processes for making such novel compounds.
    Type: Grant
    Filed: October 1, 2002
    Date of Patent: April 13, 2004
    Assignee: Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Weimin Liu, Denice M. Spero, David S. Thomson, Yancey D. Ward, Erick R. R. Young
  • Compounds useful as reversible inhibitors of cysteine proteases
    Publication number: 20040063679
    Abstract: Disclosed are novel cathepsin S, K, F, L and B reversible inhibitory compounds of the formulas (Ia) and (Ib) where R1, R2, R3, R4, R5, R6, R8, R9 and X are defined herein. The compounds are useful for treating autoimmune and other diseases. Also disclosed are processes for making such novel compounds.
    Type: Application
    Filed: September 27, 2002
    Publication date: April 1, 2004
    Applicant: Boehringer Ingelheim Pharmaceuticals Inc.
    Inventors: Younes Bekkali, Denice Mary Spero, Sanxing Sun, David S. Thomson, Yancey D. Ward, Erick R.R. Young, Eugene R. Hickey, Weimin Liu, Usha R. Patel
  • Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
    Publication number: 20040029932
    Abstract: Compounds of Formula (IA) and Formula (IB) 1
    Type: Application
    Filed: March 21, 2003
    Publication date: February 12, 2004
    Applicant: Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Younes Bekkali, Mario G. Cardozo, Christian Hanke Justus Joachim Harcken, Thomas M. Kirrane, Daniel Kuzmich, John Robert Proudfoot, Hossein Razavi, Hidenori Takahashi, David S. Thomson, Ji Wang, Renee Zindell
  • Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
    Publication number: 20040023999
    Abstract: Compounds of Formula (IA) and Formula (IB) 1
    Type: Application
    Filed: March 21, 2003
    Publication date: February 5, 2004
    Applicant: Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Younes Bekkali, Rajashehar Betageri, Mario G. Cardozo, Thomas A. Gilmore, Christian Hanke Justus Joachim Harcken, Thomas M. Kirrane, Daniel Kuzmich, John Robert Proudfoot, Doris Riether, Hidenori Takahashi, David S. Thomson, Ji Wang, Renee Zindell, Hossein Razavi
  • Compounds useful as reversible inhibitors of cysteine proteases
    Publication number: 20040006078
    Abstract: Disclosed are novel cathepsin S, K, F, L and B reversible inhibitory compounds of the formula (Ia) and (Ib) where R2, R3, R4, R5, R6, R7, R8, Het and X are defined herein. The compounds are useful for treating autoimmune and other diseases. Also disclosed are processes for making such novel compounds.
    Type: Application
    Filed: October 1, 2002
    Publication date: January 8, 2004
    Applicant: Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Younes Bekkali, Eugene R. Hickey, Weimin Liu, Usha R. Patel, Denice M. Spero, Sanxing Sun, David S. Thomson, Yancey D. Ward, Erick R. R. Young
  • Glucocorticoid mimetics, methods of making them, pharmaceutical formulations, and uses thereof
    Publication number: 20030232823
    Abstract: A compound of Formula (I) 1
    Type: Application
    Filed: January 3, 2003
    Publication date: December 18, 2003
    Applicant: Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Rajashekhar Betageri, David S. Thomson, Yan Zhang, Renee Michele Zindell
  • Compounds useful as reversible inhibitors of cysteine proteases
    Publication number: 20030232826
    Abstract: Disclosed are novel cathepsin S, K, F, L and B reversible inhibitory compounds of the formula (Ia) and (Ib) where R2, R3, R4, R5, R6, R7, R8, Het and X are defined herein. The compounds are useful for treating autoimmune and other diseases. Also disclosed are processes for making such novel compounds.
    Type: Application
    Filed: May 29, 2003
    Publication date: December 18, 2003
    Applicant: Boehringer Ingelheim Pharmaciuticals, Inc.
    Inventors: Younes Bekkali, Eugene R. Hickey, Weimin Liu, Usha R. Patel, Denice M. Spero, Sanxing Sun, David S. Thomson, Yancey D. Ward, Erick R. R. Young
  • Compounds useful as reversible inhibitors of cysteine proteases
    Publication number: 20030225271
    Abstract: Disclosed are novel cathepsin S, K, F, L and B reversible inhibitory compounds of the formulas (I), (II), (Ia) and (Ib) further defined herein. The compounds are useful for treating autoimmune diseases. Also disclosed are processes for making such novel compounds.
    Type: Application
    Filed: April 24, 2003
    Publication date: December 4, 2003
    Applicant: Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Michel Jose Emmanuel, Eugene R. Hickey, Weimin Liu, Denice Mary Spero, Sanxing Sun, David S. Thomson, Yancey David Ward, Erick Richard Roush Young
  • Compounds useful as reversible inhibitors of cysteine proteases
    Publication number: 20030225270
    Abstract: Disclosed are novel cathepsin S, K, F, L and B reversible inhibitory compounds of the formulas (I), (II), (Ia) and (Ib) further defined herein. The compounds are useful for treating autoimmune diseases. Also disclosed are processes for making such novel compounds.
    Type: Application
    Filed: April 24, 2003
    Publication date: December 4, 2003
    Applicant: Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Michel Jose Emmanuel, Eugene R. Hickey, Weimin Liu, Denice Mary Spero, Sanxing Sun, David S. Thomson, Yancey David Ward, Erick Richard Roush Young
  • Compounds useful as reversible inhibitors of cysteine proteases
    Publication number: 20030216383
    Abstract: Disclosed are novel cathepsin S, K, F, L and B reversible inhibitory compounds of the formula (Ia) and (Ib) where R2, R3, R4, R5, R6, R7, R8, Het and X are defined herein. The compounds are useful for treating autoimmune and other diseases. Also disclosed are processes for making such novel compounds.
    Type: Application
    Filed: October 1, 2002
    Publication date: November 20, 2003
    Applicant: Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Weimin Liu, Denice M. Spero, David S. Thomson, Yancey D. Ward, Erick R.R. Young